Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Elekta AB ( ($SE:EKTA.B) ).
Elekta has received U.S. FDA 510(k) clearance for its Elekta Evo CT-Linac, enabling the company to begin marketing the advanced linear accelerator to radiation oncology providers in the United States. The system incorporates Elekta’s Iris high-definition, AI-enhanced imaging to produce clearer, artifact-reduced cone-beam CT images, improving visualization of tumors, organs-at-risk and soft tissue changes during treatment, and supporting more precise, personalized radiation therapy. Already in use in Europe and other markets, Evo’s U.S. clearance strengthens Elekta’s competitive position in radiation oncology by broadening its portfolio of AI-driven imaging solutions and offering clinics—regardless of size or location—a platform designed to improve targeting accuracy, clinical decision-making and operational efficiency, with Iris imaging also engineered to be upgradable on certain existing Elekta linacs.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK52.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta is a Stockholm-headquartered leader in precision radiation therapy, developing advanced, outcome-driven and cost-efficient solutions to improve access to high-quality cancer care worldwide. With around 4,500 employees and offices in more than 40 countries, the company focuses on collaborating with healthcare providers to deliver radiotherapy systems and related technologies that enhance treatment accuracy, operational efficiency and patient outcomes.
Average Trading Volume: 1,252,955
Technical Sentiment Signal: Hold
Current Market Cap: SEK23.21B
Learn more about EKTA.B stock on TipRanks’ Stock Analysis page.